sanofi december letter to shareholders , page-3

Commenting on the Group?s performance in 2010, sanofi-aventis Chief Executive Officer, Christopher A. Viehbacher said, ?2010
was the first year in which the patent cliff really became visible with generic competition for several of our products, notably
Lovenox? in the U.S. However, we have delivered another year of EPS growth due to the excellent performance of our growth
platforms, which now account for 54% of sales, and tight cost control. In 2010, these growth platforms accounted for more than ?16
billion in sales, an increase of 12.5%, constituting a solid basis for the mid and long term development of our company.?
2010.
Aligning with Big Als message !!
regards
Q